FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999876688> ?p ?o ?g. }

• W2999876688 endingPage "534" @default.
• W2999876688 startingPage "530" @default.
• W2999876688 abstract "Objectives Intraperitoneal (IP) chemotherapy following neoadjuvant chemotherapy (NACT) and interval tumor reductive surgery (TRS) for advanced ovarian cancer is feasible, however, the impact on disease outcomes remains unclear. We compare outcomes of patients treated with IP chemotherapy versus intravenous (IV) chemotherapy following NACT and interval TRS. Methods In this retrospective review, patients with advanced ovarian cancer were included if they received NACT followed by optimal interval TRS between 1/2004 and 4/2017. Patients were excluded if they had an ECOG PS >1, received >6 cycles of NACT or postoperative chemotherapy, and/or received bevacizumab during primary therapy. Primary outcomes were progression free survival (PFS) and overall survival (OS). Results There were 134 patients included in this study, 37 (28%) received IP and 97 (72%) received IV chemotherapy postoperatively. Patients in the IV group were older (median 66.3 vs 59.7 years, p = 0.0039) though there were no differences in BMI, race, BRCA status, stage, or histology. Median PFS was 3 months longer in the IP group (14.5 versus 11.5 months, p = 0.028) however there was no significant difference in OS. On univariate analysis, increasing number of NACT cycles (HR 1.914, 95% CI 1.024–3.497) and residual disease at completion of TRS (HR 1.541, 95% CI 1.042–2.248) were associated with decreased PFS; IP chemotherapy was associated with increased PFS (HR 0.633, 95% CI 0.414–0.944). These associations remained on multivariate analysis. Toxicity was comparable between the groups. Conclusions IP after NACT and optimal interval TRS was associated with in improved PFS compared to IV chemotherapy without significant differences in toxicity." @default.
• W2999876688 created "2020-01-23" @default.
• W2999876688 creator A5005976868 @default.
• W2999876688 creator A5009863325 @default.
• W2999876688 creator A5021359849 @default.
• W2999876688 creator A5035468199 @default.
• W2999876688 creator A5037901720 @default.
• W2999876688 creator A5038248146 @default.
• W2999876688 creator A5043043036 @default.
• W2999876688 creator A5047088320 @default.
• W2999876688 creator A5059622280 @default.
• W2999876688 creator A5060497385 @default.
• W2999876688 creator A5062151371 @default.
• W2999876688 creator A5085606987 @default.
• W2999876688 creator A5089418421 @default.
• W2999876688 creator A5090429618 @default.
• W2999876688 date "2020-03-01" @default.
• W2999876688 modified "2023-10-17" @default.
• W2999876688 title "Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer" @default.
• W2999876688 cites W1922469696 @default.
• W2999876688 cites W1993931915 @default.
• W2999876688 cites W1998258610 @default.
• W2999876688 cites W2026106407 @default.
• W2999876688 cites W2036013736 @default.
• W2999876688 cites W2099373382 @default.
• W2999876688 cites W2106767659 @default.
• W2999876688 cites W2132433481 @default.
• W2999876688 cites W2154175915 @default.
• W2999876688 cites W2214690457 @default.
• W2999876688 cites W2299895389 @default.
• W2999876688 cites W2316501478 @default.
• W2999876688 cites W2526175885 @default.
• W2999876688 cites W2770677135 @default.
• W2999876688 cites W2784597821 @default.
• W2999876688 cites W2937594202 @default.
• W2999876688 doi "https://doi.org/10.1016/j.ygyno.2019.12.016" @default.
• W2999876688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31937450" @default.
• W2999876688 hasPublicationYear "2020" @default.
• W2999876688 type Work @default.
• W2999876688 sameAs 2999876688 @default.
• W2999876688 citedByCount "5" @default.
• W2999876688 countsByYear W29998766882020 @default.
• W2999876688 countsByYear W29998766882022 @default.
• W2999876688 countsByYear W29998766882023 @default.
• W2999876688 crossrefType "journal-article" @default.
• W2999876688 hasAuthorship W2999876688A5005976868 @default.
• W2999876688 hasAuthorship W2999876688A5009863325 @default.
• W2999876688 hasAuthorship W2999876688A5021359849 @default.
• W2999876688 hasAuthorship W2999876688A5035468199 @default.
• W2999876688 hasAuthorship W2999876688A5037901720 @default.
• W2999876688 hasAuthorship W2999876688A5038248146 @default.
• W2999876688 hasAuthorship W2999876688A5043043036 @default.
• W2999876688 hasAuthorship W2999876688A5047088320 @default.
• W2999876688 hasAuthorship W2999876688A5059622280 @default.
• W2999876688 hasAuthorship W2999876688A5060497385 @default.
• W2999876688 hasAuthorship W2999876688A5062151371 @default.
• W2999876688 hasAuthorship W2999876688A5085606987 @default.
• W2999876688 hasAuthorship W2999876688A5089418421 @default.
• W2999876688 hasAuthorship W2999876688A5090429618 @default.
• W2999876688 hasConcept C121608353 @default.
• W2999876688 hasConcept C126322002 @default.
• W2999876688 hasConcept C141071460 @default.
• W2999876688 hasConcept C143998085 @default.
• W2999876688 hasConcept C144301174 @default.
• W2999876688 hasConcept C146357865 @default.
• W2999876688 hasConcept C151730666 @default.
• W2999876688 hasConcept C167135981 @default.
• W2999876688 hasConcept C2776694085 @default.
• W2999876688 hasConcept C2777802072 @default.
• W2999876688 hasConcept C2780427987 @default.
• W2999876688 hasConcept C38180746 @default.
• W2999876688 hasConcept C44249647 @default.
• W2999876688 hasConcept C71924100 @default.
• W2999876688 hasConcept C86803240 @default.
• W2999876688 hasConceptScore W2999876688C121608353 @default.
• W2999876688 hasConceptScore W2999876688C126322002 @default.
• W2999876688 hasConceptScore W2999876688C141071460 @default.
• W2999876688 hasConceptScore W2999876688C143998085 @default.
• W2999876688 hasConceptScore W2999876688C144301174 @default.
• W2999876688 hasConceptScore W2999876688C146357865 @default.
• W2999876688 hasConceptScore W2999876688C151730666 @default.
• W2999876688 hasConceptScore W2999876688C167135981 @default.
• W2999876688 hasConceptScore W2999876688C2776694085 @default.
• W2999876688 hasConceptScore W2999876688C2777802072 @default.
• W2999876688 hasConceptScore W2999876688C2780427987 @default.
• W2999876688 hasConceptScore W2999876688C38180746 @default.
• W2999876688 hasConceptScore W2999876688C44249647 @default.
• W2999876688 hasConceptScore W2999876688C71924100 @default.
• W2999876688 hasConceptScore W2999876688C86803240 @default.
• W2999876688 hasIssue "3" @default.
• W2999876688 hasLocation W29998766881 @default.
• W2999876688 hasLocation W29998766882 @default.
• W2999876688 hasOpenAccess W2999876688 @default.
• W2999876688 hasPrimaryLocation W29998766881 @default.
• W2999876688 hasRelatedWork W167319750 @default.
• W2999876688 hasRelatedWork W2037617518 @default.
• W2999876688 hasRelatedWork W2042861937 @default.
• W2999876688 hasRelatedWork W2072213084 @default.

• next